MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients

Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-base...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Genomics Proteomics
Main Authors: KOVACOVA, JULIA, JURACEK, JAROSLAV, POPRACH, ALEXANDR, KOPECKY, JINDRICH, FIALA, ONDREJ, SVOBODA, MAREK, FABIAN, PAVEL, RADOVA, LENKA, BRABEC, PETR, BUCHLER, TOMAS, SLABY, ONDREJ
Formato: Artigo
Idioma:Inglês
Publicado em: International Institute of Anticancer Research 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6727077/
https://ncbi.nlm.nih.gov/pubmed/31467229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/cgp.20140
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados